Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study
Authors:
Abstract
Background: Data supporting a carry‐over effect with sublingual immunotherapy (SLIT) are scarce. This randomized, double‐blind, placebo‐controlled study evaluated the efficacy, carry‐over effect and safety of grass pollen SLIT using co‐seasonal treatment.Methods: Patients (7.9–64.7 years) with grass pollen allergy received ultra‐rush titration with increasing doses (30, 90, 150 and 300 IR) of a 5‐grass pollen mixture every 20 min at the start of the pollen seasons, followed by 300 IR daily until the end of the pollen seasons. A baseline season (no SLIT) was followed by three consecutive treatment seasons and one follow‐up season. Symptoms, medication and adverse events were documented and specific immunoglobulin (Ig)E and IgG4 measured.Results: Data were analysed for 183 of the 213 randomized patients. Mean treatment duration varied between seasons (81.8−92.7 days). Combined scores (symptoms and medication) improved progressively across treatment seasons (up to 44.7% improvement for SLIT compared with baseline) and fluctuated between −11.3% and −14.8% for placebo (P < 0.05). Similar changes were observed for symptom scores, with a successive decrease of 39.7% (SLIT) and fluctuations between +13.6% and −1.51% for placebo (P < 0.05). Combined score (P = 0.0508) and symptom score improvements (P = 0.0144) with SLIT continued during follow up. Increases in specific IgG4 observed in the first season were sustained for SLIT vs placebo throughout treatment (P = 0.0001). Titration and daily SLIT were well tolerated. No serious systemic or anaphylactic reactions were reported.Conclusions: Seasonal SLIT with ultra‐rush titration is well tolerated and effective from the first treatment season onwards. These data indicate a carry‐over effect of seasonal SLIT.Keywords
This publication has 28 references indexed in Scilit:
- Sublingual immunotherapy in pediatric allergic rhinitis and asthma: Efficacy, safety, and practical considerationsCurrent Allergy and Asthma Reports, 2007
- Specific immunotherapy has long‐term preventive effect of seasonal and perennial asthma: 10‐year follow‐up on the PAT studyAllergy, 2007
- Allergic Rhinitis and its Impact on Asthma update: Allergen immunotherapyJournal of Allergy and Clinical Immunology, 2007
- Sublingual immunotherapy in the treatment of adult allergic rhinitis patientsAllergy, 2006
- A Pilot Study of Feasibility of Ultra-Rush (20–25 Minutes) Sublingual-Swallow Immunotherapy in 679 Patients (699 Sessions) with Allergic Rhinitis and/or AsthmaInternational Journal of Immunopathology and Pharmacology, 2005
- Sublingual immunotherapy for allergic rhinitis: systematic review and meta‐analysis*Allergy, 2004
- Comparison of the clinical efficacy and safety of subcutaneous and sublingual immunotherapy: methodological approaches and experimental resultsCurrent Opinion in Allergy and Clinical Immunology, 2004
- Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitisJournal of Allergy and Clinical Immunology, 2004
- Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double‐blind placebo‐controlled studyAllergy, 2004
- Safety of Various Dosage Regimens during Induction of Sublingual ImmunotherapyInternational Archives of Allergy and Immunology, 2002